New data reveal that 4 out of 5 breast cancer patients eligible for genomic testing are not told it is available to them
Surprising statistics emerge from a European survey led by Cancer Patients Europe as part of its my Cancer my Concern (myC) initiative
Brussels, Nov. 21, 2022 (GLOBE NEWSWIRE) -- If you were diagnosed with cancer, you would hope you were being given the chance to benefit from the latest advances in the field of oncology. However, initial data from a recent patient survey conducted in five European countries by Cancer Patients Europe (CPE), with the support of Exact Sciences, demonstrate that the majority of breast cancer patients eligible for genomic testing did not even know that it was an option for them.
Genomic testing allows eligible patients with early-stage breast cancer the opportunity to benefit from personalised or precision medicine. Used as a therapy aid by physicians to tailor treatment plans to their patients’ individual cancers, genomic testing can help in some treatment decisions, including whether patients are likely to benefit from adjuvant chemotherapy. Therefore, it can spare many women with early-stage breast cancer from chemotherapy and the associated side effects. Despite the importance and growing utility of personalised medicine, the survey demonstrated that 59% of overall respondents had never heard about it.
“The data show there is an urgent need to raise awareness and understanding of the value of genomic testing in breast cancer across Europe, amongst medical professionals, patients, policy makers and payers,” states Dr Fatima Cardoso, member of the myC Survey Advisory Committee and Director of the Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal. “Genomic testing has proven its value with high evidence, and it is also cost-effective. However, it is not reimbursed nor easily available in many European countries.”
In addition, the survey data highlight the need for more information to be available to patients throughout their cancer diagnosis and treatment, especially from medical professionals whom they quoted as their preferred source of information. Specifically, respondents said they would have liked to receive more information on their type of cancer, additional testing, treatment options and long-term treatment effects.
“The results of the survey bring to light some shocking truths in the treatment and management of cancer patients across Europe,” said Conchi Biurrun, Board Secretary, CPE. “Cancer Patients Europe is dedicated to accelerating discussions with policymakers and other key stakeholders to raise awareness of genomic testing and ensure its implementation into routine clinical practice to help determine whether patients should undergo chemotherapy.”
Dr Steven Bellamy, Chief Medical Officer, International, Exact Sciences, said, “we are delighted to support CPE’s myC initiative, a programme that is proving critical in our understanding of cancer care across Europe. As the data point to a significant gap in the knowledge of genomic testing, this collaboration supports an important shared goal: helping patients, and we are honoured to be a part of it”.
About the myC Patient Survey in Genomics and Breast Cancer
- The 42-question survey was completed by a total of 1,383 respondents across five countries (France, Germany, Italy, Spain, UK) over a six-week period in September/October 2022.
- Eighty-three percent (83%) of respondents were breast cancer patients, 50% of whom were eligible for genomic testing.
- Eighty-four percent (84%) of eligible patients stated they did not have enough information to make a decision on whether to take a genomic test.
- Only a quarter (25%) of eligible patients took a genomic test.
About Cancer Patients Europe (CPE)
Cancer Patients Europe is a recently established pan-European, pan-cancer association. The association’s mission is to provide a balanced representation of cancer patients and their experiences across Europe, bridging the gap between European and national practice implementation and reducing the burden of cancer on patients and survivors, their caregivers, healthcare systems, and society as a whole.
About the my Cancer my Concern (myC) Initiative
myC is a CPE initiative which aims to raise awareness of the benefits and values of genomic testing in cancer. Personalised treatment decisions are key to this effort and genomic testing is an example of current progress in this area. The project is part of CPE’s broader goal to improve the management of cancer for patients across Europe and call European policymakers to action.
The myC initiative is supported by Exact Sciences, a cancer diagnostics company.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Terra Balcanica Announces Private Placement Financing1.12.2023 23:00:00 CET | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA) announces the intent to complete a non-brokered, private placement (“Private Placement”) for gross proceeds of up to $150,000 through the issuance of up to 3,750,000 common shares (“Common Shares”) at a purchase price of $0.04 per share. The Common Shares will be offered by way of prospectus exemptions in Canada and the Common Shares sold in the Private Placement will be subject to a hold period of four months plus one day. The Closing Date is expected to occur on or about December 11th, 2023, subject to regulatory approvals, including the approval by the CSE and certain other customary conditions including, but not limited to, execution of subscription agreements between the Company and the subscribers. The Private Placement will be utilized for opportuniti
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu
Havila Kystruten AS: Regnskap for tredje kvartal 20231.12.2023 18:34:33 CET | Pressemelding
September var første måned med full drift av alle fire skip. Til tross for forsinkelse av Havila Polaris og Havila Pollux i Q3, ble gjennomsnittlig belegg 70 % og gjennomsnittlig lugarrate kr 4 466. Inntektene er naturligvis preget av forsinkelsene og lavere enn forventet, men selskapet ser en positiv inntektsutvikling fra 2. kvartal og videre ut året. I forbindelse med refinansiering er driftskostnadene påvirket av ekstraordinære kostnader knyttet til juridiske og finansielle rådgivere. Regnskap og balanse påvirkes av valutasvingningene, og selskapet sikrer sine valutaforpliktelser med salg i valuta. Selskapet legger til grunn en normalisert drift av fire skip fremover, uten ekstraordinære kostnader. Selskapet har ambisjoner om et gjennomsnittlig belegg på 80 % for 2024, hvorav 45 % av all kapasitet allerede er solgt. Interessen for Havila Kystruten øker stadig i både inn- og utland, og positive tilbakemeldinger om produkt og konsept mottas på daglig basis. Resultat for 3. kvartal 202
Havila Kystruten : Third quarter 2023 accounts1.12.2023 18:34:33 CET | Press release
September marked the first month of full operation for all four ships. Despite the delays with Havila Polaris and Havila Pollux in Q3, the average occupancy rate reached 70%, with an average cabin rate of NOK 4,466. Revenues are naturally affected by the delays and lower than expected, but the company sees a positive revenue trend from the 2nd quarter and onward throughout the year. In connection with refinancing, operating costs were affected by extraordinary expenses related to legal and financial advisors. Currency fluctuations have had an impact on the financial statements and balance sheet, and the company is hedging its currency commitments through currency sales. The company assumes normalized operation of four ships going forward, without extraordinary costs. The company aims for an average occupancy rate of 80% for 2024, with 45% of all capacity already sold. Interest in Havila Kystruten is continually growing both domestically and internationally, with positive feedback on th
Resultat af aktietilbagekøb1.12.2023 17:41:01 CET | pressemeddelelse
Selskabet meddelte i selskabsmeddelelse 30/2023, at man havde besluttet at iværksætte et aktietilbagekøb på køb af optil 1.000.000 aktier til kurs 2.50 svarende til maksimalt DKK 2.5 mio. i perioden 22. november – 1. december 2023, begge dage inklusive. I hele perioden har der været indlagt en synlig stående budordrer i kurs 2.50, så markedet løbende har kunne følge tilbagekøbets udvikling, og som det også fremgik af selskabsmeddelelse 30/2023, så stod alle insidere tilbage for selskabets aktionærer, så insidere som ønskede at sælge aktier kun kunne tilbagesælge aktier den sidste dag, dvs. fra og med fredag d. 1. december 2023 kl. 09.00. Resultatet af insidernes evt. frasalg vil fremgå af en separat meddelelse. Resultatet af aktietilbagekøbsprogrammet blev at selskabet har tilbagekøbt 19.687 aktier til kurs 2.50 svarende til DKK 49.217,50. Selskabet ejer pr. dags dato totalt 4.854.063 egne aktier svarende til 9,06 % af selskabets aktiekapital. Det samlede antal aktier i virksomheden er